NONALCOHOLIC STEATOHEPATITIS
Clinical trials for NONALCOHOLIC STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug HPG1860 shows promise in reducing liver fat in NASH patients
Disease control CompletedThis study tested three different doses of HPG1860, an experimental oral drug, against a placebo in 89 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. The main goals were to check safety and see if the drug could lower liver fat content measured by…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Hepagene (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Can vitamin e tame fatty liver? new study tests the right dose
Disease control CompletedThis study tested different doses of vitamin E in 200 adults with nonalcoholic fatty liver disease (NAFLD) to find the best dose for improving liver health. Participants took vitamin E or a placebo for 24 weeks, and researchers measured changes in a key liver enzyme (ALT). The go…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Can an allergy drug help fatty liver? new study says maybe
Disease control CompletedThis study looked at whether ketotifen, a medicine used for allergies, is safe and helpful for people with non-alcoholic fatty liver disease (NAFLD) who do not have cirrhosis. Sixty adults with NAFLD took part. The main goal was to see if ketotifen could improve liver scarring (f…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE4 • Sponsor: Tanta University • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug shows promise against fatty liver disease in major trial
Disease control CompletedThis study tested an experimental drug called efinopegdutide in 381 adults with non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The main goal was to see if the drug could help the liver heal (resolve NASH) without making scarring worse. Participants r…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could a drug combo reverse liver scarring in NASH patients?
Disease control CompletedThis phase 2 trial tested whether semaglutide (a diabetes drug) combined with cilofexor and firsocostat (two experimental liver drugs) can improve liver scarring and resolve NASH in people with cirrhosis. 457 participants with compensated cirrhosis due to NASH were randomly assig…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New shot targets genetic form of fatty liver disease
Disease control CompletedThis study tested a monthly injection called AZD2693 in 220 adults with non-alcoholic steatohepatitis (NASH) and liver scarring, who carry a specific genetic risk factor. The goal was to see if the drug could reverse liver inflammation and scarring without making it worse. The tr…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug shows promise against fatty liver and scarring
Disease control CompletedThis phase 2b trial tested whether saroglitazar magnesium can help people with nonalcoholic steatohepatitis (NASH) and liver fibrosis. 189 adults took either a 2 mg or 4 mg dose of the drug or a placebo daily for several months. The main goal was to see if the drug could resolve …
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Massive study tracks fatty liver disease patients to uncover Real-World treatment patterns
Knowledge-focused CompletedThis study followed over 7,300 people with nonalcoholic fatty liver disease (NAFLD) and its more severe form, NASH, in regular doctor visits. Researchers aimed to understand how the disease progresses and what treatments doctors are using, since no drugs are officially approved f…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC